{
    "ticker": "SYBX",
    "name": "Synlogic, Inc.",
    "description": "Synlogic, Inc. is a clinical-stage biotechnology company focused on developing groundbreaking medicines using its proprietary Synthetic Biotic platform. Founded in 2014 and headquartered in Cambridge, Massachusetts, Synlogic is dedicated to creating engineered bacteria that can be used to treat a range of diseases by restoring metabolic balance. The company\u2019s innovative approach involves designing microbes that can be administered orally and programmed to perform specific functions within the human body, effectively acting as living therapeutics. Synlogic's lead product candidate, SYNB1618, is being developed for the treatment of phenylketonuria (PKU), a rare genetic disorder that leads to the accumulation of phenylalanine, which can cause serious health issues. Additionally, Synlogic is exploring other indications, including metabolic diseases and autoimmune disorders. With a strong focus on research and development, Synlogic aims to transform the treatment landscape for patients with unmet medical needs and contribute significantly to the field of synthetic biology. The company's mission is to leverage its Synthetic Biotic technology to deliver effective, safe, and accessible therapies that improve patient outcomes and quality of life.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2014",
    "website": "https://www.synlogic.com",
    "ceo": "David H. L. H. de Graaf, Ph.D.",
    "social_media": {
        "twitter": "https://twitter.com/synlogic",
        "linkedin": "https://www.linkedin.com/company/synlogic/"
    },
    "investor_relations": "https://investors.synlogic.com",
    "key_executives": [
        {
            "name": "David H. L. H. de Graaf, Ph.D.",
            "position": "CEO"
        },
        {
            "name": "Megan R. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Lead Product Candidate",
            "products": [
                "SYNB1618"
            ]
        },
        {
            "category": "Pipeline Candidates",
            "products": [
                "SYNB8802",
                "SYNB1934"
            ]
        }
    ],
    "seo": {
        "meta_title": "Synlogic, Inc. | Engineered Microbes for Therapeutic Solutions",
        "meta_description": "Explore Synlogic, Inc., a biotechnology company developing engineered microbes as living therapeutics. Learn about their innovative approach and lead product candidate for treating PKU.",
        "keywords": [
            "Synlogic",
            "Synthetic Biology",
            "Biotechnology",
            "Living Therapeutics",
            "SYNB1618",
            "PKU",
            "Phenylketonuria"
        ]
    },
    "faq": [
        {
            "question": "What does Synlogic focus on?",
            "answer": "Synlogic focuses on developing engineered bacteria as medicines to treat a variety of diseases."
        },
        {
            "question": "Who is the CEO of Synlogic?",
            "answer": "David H. L. H. de Graaf, Ph.D. is the CEO of Synlogic, Inc."
        },
        {
            "question": "Where is Synlogic headquartered?",
            "answer": "Synlogic is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is SYNB1618?",
            "answer": "SYNB1618 is Synlogic's lead product candidate being developed for the treatment of phenylketonuria (PKU)."
        },
        {
            "question": "When was Synlogic founded?",
            "answer": "Synlogic was founded in 2014."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NTLA",
        "BLRX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BMY"
    ]
}